InMed Pharmaceuticals (INM) Change in Accured Expenses (2019 - 2026)
InMed Pharmaceuticals' (INM) quarterly Change in Accured Expenses came in at $113837.0 in Q1 2026, up 270.87% year-on-year from $30694.4 in Q1 2025, and up 295.1% quarter-over-quarter from -$58348.0 in Q4 2025.
InMed Pharmaceuticals (INM) Change in Accured Expenses (2019 - 2026) Analysis & Trends
InMed Pharmaceuticals' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at $113837.0 for Q1 2026.
- On a quarterly basis, Change in Accured Expenses rose 270.87% year-over-year to $113837.0 in Q1 2026; TTM through Mar 2026 was -$118906.0, a 198.0% decrease from a year earlier, with the FY2025 full-year figure at -$249728.0, down 651.5% from the prior year.
- Change in Accured Expenses climbed to $113837.0 in Q1 2026 per INM's latest filing, from -$58348.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $470728.0 in Q2 2024 and bottomed at -$642392.0 in Q3 2024.
- The 5-year median for Change in Accured Expenses is -$104340.0 (2024), against an average of -$137505.2.
- Across the five-year window, Change in Accured Expenses tumbled 253.19% in 2023 and jumped 312.82% in 2024, its largest moves.
- Year by year, Change in Accured Expenses stood at -$349611.0 in 2022, then surged by 169.04% to $241378.0 in 2023, then surged by 48.98% to $359614.0 in 2024, then sank by 116.23% to -$58348.0 in 2025, then soared by 295.1% to $113837.0 in 2026.
- Per Business Quant, the three latest INM Change in Accured Expenses figures stand at $113837.0 (Q1 2026), -$58348.0 (Q4 2025), and -$274066.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.55 Bn | 87.69 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 36.00 Bn | 32.26 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.45 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.47 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.47 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | InMed Pharmaceuticals | 6.88 Mn | 1.64 Mn | - | 113,837.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 113,837.00 |
| Mar 31, 2026 | 113,837.00 |
| Dec 31, 2025 | -58,348.00 |
| Dec 31, 2025 | -58,348.00 |
| Sep 30, 2025 | -274,066.00 |
| Sep 30, 2025 | -274,066.00 |
| Jun 30, 2025 | 99,671.00 |
| Jun 30, 2025 | 99,671.00 |
| Mar 31, 2025 | -66,621.00 |
| Mar 31, 2025 | -66,621.00 |
| Dec 31, 2024 | 359,614.00 |
| Dec 31, 2024 | 359,614.00 |
| Sep 30, 2024 | -642,392.00 |
| Sep 30, 2024 | -642,392.00 |
| Jun 30, 2024 | 470,728.00 |
| Jun 30, 2024 | 470,728.00 |
| Mar 31, 2024 | -104,340.00 |
| Mar 31, 2024 | -104,340.00 |
| Dec 31, 2023 | 241,378.00 |
| Dec 31, 2023 | 241,378.00 |